{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T20:45:20Z","timestamp":1763585120909,"version":"3.40.5"},"reference-count":15,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:p> BACKGROUND: Non-tuberculous mycobacteria (NTM) are an uncommon but serious cause of peritoneal dialysis (PD)\u2013related infections. NTM peritonitis typically necessitates PD catheter removal, PD withdrawal, and aggressive, prolonged antimicrobial treatment. Few reported cases of NTM peritonitis in the pediatric population exist. METHODS: We describe a case of a 9-year-old boy on PD after kidney allograft failure who developed Mycobacterium fortuitum peritonitis, and we summarize the available literature on M. fortuitum peritonitis in pediatric patients receiving PD. RESULTS AND CONCLUSION: Therapeutic options were limited by adverse medication effects and risk of drug\u2013drug interactions in a patient with complex mental health comorbidities. Clofazimine presented an acceptable oral treatment option for long-term therapy in combination with ciprofloxacin and was well tolerated by this patient. Prompt PD catheter removal followed by 6 months of dual antimicrobial therapy resulted in a full recovery and successful re-transplantation with no infection relapse. <\/jats:p>","DOI":"10.3138\/jammi-2021-0029","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:18:52Z","timestamp":1643750332000},"page":"125-130","source":"Crossref","is-referenced-by-count":4,"title":["<i>Mycobacterium fortuitum<\/i> peritoneal dialysis-related peritonitis in a child: A case report and review of the literature"],"prefix":"10.3138","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-301X","authenticated-orcid":true,"given":"Kathryn","family":"Haubrich","sequence":"first","affiliation":[{"name":"Department of Pharmacy, BC Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-8746","authenticated-orcid":true,"given":"Cherry","family":"Mammen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, BC Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-7932","authenticated-orcid":true,"given":"Inna","family":"Sekirov","sequence":"additional","affiliation":[{"name":"BC Center for Disease Control Public Health Laboratory, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-0779","authenticated-orcid":true,"given":"Hana","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, BC Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","reference":[{"unstructured":"1. Bunke M, Brier ME, Golper TA. Culture-negative CAPD peritonitis: the Network 9 Study. Adv Perit Dial. 1994; 10:174.","key":"r1"},{"issue":"4","key":"r2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ndt\/gfr504","volume":"27","author":"Song Y","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"r3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000485716","volume":"196","author":"Washida N","year":"2018","journal-title":"Contrib Nephrol"},{"issue":"2","key":"r4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0732-8893(86)90151-3","volume":"4","author":"LaRocco MT","year":"1986","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"r5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0272-6386(12)80303-9","volume":"18","author":"Dunmire RB","year":"1991","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"r6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"Griffith DE","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"r7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4065\/79.7.927","volume":"79","author":"Rho JP","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"r8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1086\/504809","volume":"43","author":"Taylor JJ","year":"2006","journal-title":"Clin Infect Dis"},{"key":"r9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1517\/17425255.2015.1098617","volume":"11","author":"Douros A","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"unstructured":"10. Lamprene (clofazimine) [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals; 2019.","key":"r10"},{"issue":"3","key":"r11","doi-asserted-by":"crossref","first-page":"ofx147","DOI":"10.1093\/ofid\/ofx147","volume":"4","author":"McGuffin SA","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"r12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jpids\/piz049","volume":"9","author":"Adler-Shohet FC","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"12","key":"r13","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","volume":"56","author":"Van Ingen J","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"r14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","volume":"35","author":"Shen G-H","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"r15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0896860820909702","volume":"41","author":"Pinapala A","year":"2021","journal-title":"Perit Dial Int"}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi-2021-0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:00:36Z","timestamp":1741878036000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi-2021-0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6,1]]}},"alternative-id":["10.3138\/jammi-2021-0029"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2021-0029","relation":{},"ISSN":["2371-0888","2371-0888"],"issn-type":[{"type":"print","value":"2371-0888"},{"type":"electronic","value":"2371-0888"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}